IMRT Combined With Erlotinib for EGFR Wild Type Non-small Cell Lung Cancer With 4-10 Brain Metastases

Sponsor
Sun Yat-sen University
Study ID
NCT02556593
Phase
PHASE2
Status
Terminated

Conditions

  • Non-Small Cell Lung Carcinoma

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • IMRT — RADIATION
    Daily IMRT at 45 Gy in 15 fractions to brain metastases
  • WBRT — RADIATION
    3DCRT at 30 Gy in 10 fractions to whole brain
  • erlotinib — DRUG
    erlotinib 150mg daily

Study Details

This study is to assess the efficacy of IMRT combined with erlotinib compared with whole-brain radiotherapy for EGFR wild type non-small cell lung cancer with 4-10 brain metastases.

Key Dates

First listed
Sep 22, 2015
Start date
Sep 30, 2015
Status verified
Apr 2019
Primary completion
Apr 30, 2019
Completion
Apr 30, 2019

Study Design

Enrollment
12 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: IMRT & erlotinib
    Patients in experimental group receive IMRT and erlotinib: Daily IMRT(45Gy in 15 fractions) to the brain metastases with daily erlotinib(150mg.po) for three weeks
  • Active Comparator: whole-brain radiotherapy
    Patients in this group receive WBRT at 30Gy in 10 fractions

Primary Outcome Measure

CNS progression free survival [ Time Frame: 2 years ]

Related Studies